Clinical Trial Update: Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating masitinib in metastatic melanoma with a c-KIT juxtamembrane domain mutation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Metastatic Melanoma | Phase 3 | Status: TERMINATED